Arca
Skip to content
Tools
Tools

EGFR: Epidermal growth factor receptor

Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses.

  • Drugs that act on it: 70
  • Approved: 15
  • In phases 1 to 3: 55
  • Sponsors: 37

Who is on it, and how far along

Every drug ChEMBL records acting on EGFR, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 47
  • Antibody 15
  • Antibody-drug conjugate 3
  • Other 5

Approved15

Phase 318

Phase 225

Phase 112

Sponsors

Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

The landscape

Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 60 of 70 act as: Epidermal growth factor receptor erbB1 inhibitor; the rest name their own mechanism.
CetuximabBoxed warningApprovedEli LillyAntibodyInhibitor293
OsimertinibApprovedAstraZeneca PharmaceuticalsSmall moleculeInhibitor204
PanitumumabBoxed warningApprovedAmgenAntibodyInhibitor62
AmivantamabApprovedJohnson & JohnsonAntibodyInhibitor49
ErlotinibApprovedAstellas PharmaSmall moleculeInhibitor33
NeratinibApprovedPuma BiotechnologySmall moleculeInhibitor33
AfatinibApprovedArriVent BioPharma, Inc.Small moleculeInhibitor28
LazertinibApprovedJohnson & JohnsonSmall moleculeInhibitor23
BrigatinibApprovedTakeda Pharmaceuticals USASmall moleculeInhibitor17
GefitinibApprovedAstraZeneca PharmaceuticalsSmall moleculeInhibitor16
LapatinibBoxed warningApprovedTianjin Hemay Pharmaceutical Co., LtdSmall moleculeInhibitor9
NecitumumabBoxed warningApprovedEli LillyAntibodyInhibitor3
MobocertinibBoxed warningApprovedTakeda Pharmaceuticals USASmall moleculeInhibitor1
Dacomitinib anhydrousApprovedPfizerSmall moleculeInhibitor0
OlmutinibApprovedHanmi Pharmaceutical Company LimitedSmall moleculeInhibitor0
PyrotinibPhase 3RemeGen Co., Ltd.Small moleculeInhibitor99
NimotuzumabPhase 3—AntibodyInhibitor54
AumolertinibPhase 3Suzhou Suncadia Biopharmaceuticals Co., Ltd.Small moleculeInhibitor38
FirmonertinibPhase 3ArriVent BioPharma, Inc.Small moleculeInhibitor16
IcotinibPhase 3Betta Pharmaceuticals Co., Ltd.Small moleculeInhibitor10
CLN-081Phase 3Taiho OncologySmall moleculeInhibitor5
AbivertinibPhase 3Hangzhou ACEA Pharmaceutical Research Co., Ltd.Small moleculeInhibitor0
CanertinibPhase 3PfizerSmall moleculeInhibitor0
Depatuxizumab mafodotinPhase 3AbbVieAntibody-drug conjugateBinding agentEpidermal growth factor receptor erbB1 binding agent0
FutuximabPhase 3Symphogen A/SAntibodyAntagonistEpidermal growth factor receptor erbB1 antagonist0
ModotuximabPhase 3—AntibodyAntagonistEpidermal growth factor receptor erbB1 antagonist0
NaquotinibPhase 3Astellas PharmaSmall moleculeInhibitor0
RindopepimutPhase 3Celldex TherapeuticsOtherVaccine antigenEpidermal growth factor receptor erbB1 vaccine antigen0
RociletinibPhase 3Clovis Oncology, Inc.Small moleculeInhibitor0
RuserontinibPhase 3CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Small moleculeInhibitor0
SimotinibPhase 3Jiangsu Simcere Pharmaceutical Co., Ltd.Small moleculeInhibitor0
TesevatinibPhase 3SanofiSmall moleculeInhibitor0
ZalutumumabPhase 3GenmabAntibodyAntagonistEpidermal growth factor receptor erbB1 antagonist0
MatuzumabPhase 2Shanghai Henlius BiotechAntibodyInhibitor5
Cetuximab sarotalocanPhase 2Rakuten Medical, Inc.Antibody-drug conjugateBinding agentEpidermal growth factor receptor erbB1 binding agent2
NazartinibPhase 2Novartis PharmaceuticalsSmall moleculeInhibitor2
AZD-3759Phase 2Alpha Biopharma (Jiangsu) Co., Ltd.Small moleculeInhibitor1
SapitinibPhase 2AstraZeneca PharmaceuticalsSmall moleculeInhibitor1
AEE-788Phase 2Novartis PharmaceuticalsSmall moleculeInhibitor0
AllitinibPhase 2—Small moleculeInhibitor0
BafisontamabPhase 2—AntibodyInhibitor0
BMS-690514Phase 2Bristol-Myers SquibbSmall moleculeInhibitor0
CEP-32496Phase 2RocheSmall moleculeInhibitor0
DepatuxizumabPhase 2AbbVieAntibodyInhibitor0
DuligotuzumabPhase 2RocheAntibodyInhibitor0
FalnidamolPhase 2—Small moleculeInhibitor0
GC1118Phase 2—OtherInhibitor0
ImgatuzumabPhase 2RocheAntibodyAntagonistEpidermal growth factor receptor erbB1 antagonist0
Losatuxizumab vedotinPhase 2—Antibody-drug conjugateBinding agentEpidermal growth factor receptor binding agent0
MAB-425Phase 2—OtherInhibitor0
MavelertinibPhase 2PfizerSmall moleculeInhibitor0
MDX-447Phase 2—OtherCross-linking agentEpidermal growth factor receptor erbB1 cross-linking agent0
PelitinibPhase 2Wyeth is now a wholly owned subsidiary of PfizerSmall moleculeInhibitor0
PF-06459988Phase 2PfizerSmall moleculeInhibitor0
PimurutamabPhase 2Shanghai Henlius BiotechAntibodyInhibitor0
TheliatinibPhase 2Hutchison Medipharma LimitedSmall moleculeInhibitor0
TomuzotuximabPhase 2Glycotope GmbHAntibodyInhibitor0
VarlitinibPhase 2—Small moleculeInhibitor0
AC-480Phase 1Daiichi SankyoSmall moleculeInhibitor0
AV-412 free basePhase 1LG ChemSmall moleculeInhibitor0
AZD-4769Phase 1—Small moleculeInhibitor0
CUDC-101Phase 1Curis, Inc.Small moleculeInhibitor0
EpitinibPhase 1Hutchison Medipharma LimitedSmall moleculeInhibitor0
JNJ-26483327Phase 1Johnson & JohnsonSmall moleculeInhibitor0
PD-0166285Phase 1—Small moleculeInhibitor0
PKI-166Phase 1—Small moleculeInhibitor0
PuquitinibPhase 1—Small moleculeInhibitor0
S-222611Phase 1—OtherInhibitor0
TAK-285Phase 1Takeda Pharmaceuticals USASmall moleculeInhibitor0
TuxobertinibPhase 1Black Diamond Therapeutics, Inc.Small moleculeNegative allosteric modulatorEpidermal growth factor receptor erbB1 negative allosteric modulator0

Open trials

The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 129 in all, from ClinicalTrials.gov.
A Phase 2 Study of Bevacizumab Plus Erlotinib in EGFR-Amplified Metastatic Colorectal CancerErlotinibPhase 2Not yet recruitingKorea University Anam HospitalNov 17, 2026
A Study of BMS-986548 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid MalignanciesCetuximabPhase 1 / Phase 2Not yet recruitingBristol-Myers SquibbNov 16, 2026
A Study of BI 4015092, Alone or in Combination With Other Cancer Treatment, in Patients With Advanced Cancer That Has a KRAS G12D MutationCetuximabPhase 1Not yet recruitingBoehringer IngelheimNov 9, 2026
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic CancerNimotuzumabPhase 2Enrolling by invitationFudan UniversityNov 6, 2026
A Project Assessing the Safety and Feasibility of Using Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Ovarian Cancer During Surgical ProceduresPanitumumabPhase 1Not yet recruitingUniversity of Alabama at BirminghamNov 5, 2026
Real-World Study: Panitumumab N01 vs Cetuximab Plus FOLFOX in First-Line RAS Wild-Type mCRCCetuximab, Panitumumab—Not yet recruitingFujian Medical University Union HospitalNov 4, 2026
Circulating Tumor DNA Methylation-Guided Adjuvant Therapy Decision-Making in Patients With Resectable Colorectal Cancer Liver Metastases After ResectionCetuximabPhase 2RecruitingFudan UniversityNov 4, 2026
A Phase Ib/II Study of GFH276 in Combination With Chemotherapy (± Bevacizumab) or Cetuximab in Patients With RAS-mutant Metastatic Colorectal CancerCetuximabPhase 1 / Phase 2Not yet recruitingGenfleet Therapeutics (Shanghai) Inc.Nov 4, 2026
GFH375 Plus Cetuximab vs Investigator's Choice of Treatment in KRAS G12D-Mutant Refractory Metastatic Colorectal CancerCetuximabPhase 3Not yet recruitingGenfleet Therapeutics (Shanghai) Inc.Nov 3, 2026
A KRAS Inhibitor in Participants With Advanced Solid TumorsCetuximabPhase 1 / Phase 2RecruitingEnsem TherapeuticsNov 3, 2026
Osimertinib Plus Stereotactic Radiosurgery/Radiotherapy for EGFR-Mutant Non-Small Cell Lung Cancer With Symptomatic Brain MetastasesOsimertinibPhase 2RecruitingCho Ray HospitalNov 2, 2026
A Study to Evaluate the Safety and Effectiveness of Different Doses of RO7836748 Alone or in Combination With Other Cancer Therapies in People With Solid Tumors With a Rat Sarcoma Viral Oncogene Homolog Glycine 12 Valine (RAS G12V) MutationCetuximabPhase 1Not yet recruitingHoffmann-La RocheOct 30, 2026
Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma: A Prospective, Single-Arm Clinical StudyNimotuzumabPhase 2RecruitingCancer Institute and Hospital, Chinese Academy of Medical SciencesOct 30, 2026
A Clinical Study Comparing the Efficacy and Safety of Befotertinib Versus Icotinib in Patients With Previously Untreated EGFR-sensitive Mutation-positive Non-small Cell Lung Cancer With ECOG Score ≥2IcotinibPhase 4Not yet recruitingZhou ChengzhiOct 28, 2026
ASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLCOsimertinibPhase 3Not yet recruitingJiangsu Aosaikang Pharmaceutical Co., Ltd.Oct 27, 2026
Implantable Microdevices for in Situ Evaluation of Drug Responses in Lung CancerOsimertinibEarly phase 1RecruitingOliver JonasOct 23, 2026
Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast CancerPyrotinibPhase 3Not yet recruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOct 23, 2026
Firmonertinib Plus Chemotherapy for Unresectable EGFR PACC-Mutant Stage III Lung Cancer: A Phase II StudyFirmonertinibPhase 2Not yet recruitingHunan Province Tumor HospitalOct 16, 2026
Osimertinib and Cyclosporine A to Enhance Antitumor Efficacy in NSCLCOsimertinibPhase 2RecruitingNYU Langone HealthOct 15, 2026
MRD-Guided Aumolertinib-Based Adjuvant Therapy for Resected EGFR-Mutant NSCLCAumolertinibNot applicableNot yet recruitingPeking University People's HospitalOct 14, 2026
An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer.AumolertinibPhase 2RecruitingSuzhou Suncadia Biopharmaceuticals Co., Ltd.Oct 7, 2026
A Study to Evaluate the Safety and Activity of GDC-7035 With Anti-Cancer Therapies in Participants With KRAS G12D-Mutated Unresectable Advanced or Metastatic Colorectal Cancer or Pancreatic Ductal AdenocarcinomaPanitumumabPhase 1Not yet recruitingGenentech, Inc.Oct 5, 2026
Adjuvant EGFR-TKI Therapy After Surgery for EGFR-Mutant High-Risk Stage IA2-IIB NSCLCErlotinib, Gefitinib, Osimertinib, Aumolertinib, Icotinib—RecruitingTongji HospitalSep 23, 2026
A Phase II Study of Trastuzumab Deruxtecan (T-DXd) Plus Pyrotinib in HER2-Positive Advanced Breast Cancer After Progression on T-DXdPyrotinibPhase 2Not yet recruitingFujian Medical UniversitySep 23, 2026
Lenvatinib Plus Tislelizumab With or Without Gefitinib for Advanced Liver CancerGefitinibPhase 2Not yet recruitingFirst Affiliated Hospital of Wenzhou Medical UniversitySep 21, 2026
Pharmacokinetic (PK) Study of QL1203 and Vectibix® for the Treatment of RAS Wild-type Metastatic Colorectal CancerPanitumumabPhase 1Not yet recruitingQilu Pharmaceutical Co., Ltd.Sep 21, 2026
Nimotuzumab Plus Radiotherapy in Elderly Patients With Locally Advanced Head and Neck Squamous Cell CarcinomaMatuzumab, NimotuzumabPhase 2Not yet recruitingKe HuSep 15, 2026
Becotatug Vedotin Plus Pucotenlimab and Platinum Chemotherapy in Locally Advanced Epidermal Growth Factor Receptor (EGFR)-Positive Head and Neck Squamous Cell CarcinomaMatuzumabPhase 2RecruitingXuekui LiuSep 10, 2026
Pyrotinib for HER2-Positive Advanced Breast Cancer Previously Treated With Trastuzumab and PertuzumabPyrotinib—Active, not recruitingBeijing 302 HospitalSep 9, 2026
Amivantamab in Patients With Metastatic/Recurrent Penile Squamous Cell CarcinomaAmivantamabPhase 2Not yet recruitingLatin American Cooperative Oncology GroupSep 8, 2026
Neoadjuvant Therapy With Firmonertinib Combined With Anlotinib and Platinum-Based Doublet Chemotherapy for Resectable EGFR-Mutated NSCLCFirmonertinibPhase 2Not yet recruitingHubei Cancer HospitalSep 8, 2026
Real World Study of Icotinib in Adjuvant Post Surgical Treatment for Stage IA2 High Risk to IB EGFR Mutant Non Small Cell Lung CancerIcotinib—RecruitingBetta Pharmaceuticals Co., Ltd.Sep 8, 2026
Molecularly Tailored Therapy in Advanced Pancreatic CancerErlotinibPhase 2Not yet recruitingHerlev HospitalSep 3, 2026
JIN-A02 Plus Amivantamab in EGFR-Mutant NSCLC After Third-Generation EGFR-TKI FailureAmivantamabPhase 1Not yet recruitingYonsei UniversitySep 2, 2026
Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBCPyrotinibPhase 3RecruitingShanghai Jiao Tong University School of MedicineSep 1, 2026
SHR-A1811 Monotherapy or Sequential THPy as Neoadjuvant Therapy for Stage II-III HER2-Positive Breast CancerPyrotinibPhase 2Not yet recruitingFirst Affiliated Hospital of Zhejiang UniversityAug 26, 2026
A Randomized Study to Evaluate the Efficacy of a Reduced Starting Dose of Lazertinib (Leclaza) and Preemtive Magnesium Supplementation to Prevent Lazertinib(Leclaza)-Induced Peripheral NeuropathyLazertinibPhase 2RecruitingSamsung Medical CenterAug 19, 2026
A Multicenter Exploratory Clinical Study of Iruplaltinib Combined With Pemetrexed as Neoadjuvant Therapy for Resectable ALK-Positive Non-Squamous Non-Small Cell Lung CancerBrigatinibPhase 2Not yet recruitingFirst Affiliated Hospital of Fujian Medical UniversityAug 18, 2026
Neoadjuvant Presurgical Becotatug Vedotin (MRG003) Plus Pucotenlimab (HX008) in Oral Cavity Squamous Cell CarcinomaMatuzumabPhase 2Not yet recruitingSun Yat-sen UniversityAug 17, 2026
Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast CancerPyrotinibPhase 2Not yet recruitingFujian Cancer HospitalAug 14, 2026
Amivantamab Combined With Intrathecal Pemetrexed for LM From EGFR-Mutated Lung AdenocarcinomaAmivantamabPhase 1 / Phase 2RecruitingSecond Affiliated Hospital, Zhejiang University, School of MedicineAug 4, 2026
Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head and Neck Squamous Cell CarcinomaPanitumumabPhase 1RecruitingVanderbilt-Ingram Cancer CenterAug 3, 2026
Osimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic Non-Small Cell Lung CancerOsimertinibPhase 3RecruitingNational Taiwan University HospitalJul 31, 2026
A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic CancerNimotuzumabPhase 1 / Phase 2Not yet recruitingZhejiang UniversityJul 30, 2026
Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast CancerNeratinibPhase 2Not yet recruitingUniversity of California, San DiegoJul 27, 2026
A Phase 2 Study of ABSK043 Combined With OsimertinibOsimertinibPhase 2Not yet recruitingAbbisko Therapeutics Co, LtdJul 17, 2026
Efficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab "Immune Sandwich" Regimen Versus Full-Course Immunotherapy for Locally Advanced Nasopharyngeal CarcinomaNimotuzumabPhase 3RecruitingSun Yat-sen UniversityJul 16, 2026
Nimotuzumab Combined With the Stupp Regimen for Postoperative Residual GlioblastomaNimotuzumabPhase 2Not yet recruitingTianjin First Central HospitalJul 16, 2026
Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab FailurePyrotinibPhase 1 / Phase 2RecruitingTianjin Medical University Cancer Institute and HospitalJul 16, 2026
A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung CancerLazertinib, Osimertinib, AumolertinibPhase 1 / Phase 2RecruitingVoronoi, IncJul 13, 2026
First-line Therapy With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor(EGFR-TKI) Combined With Trastuzumab Rezetecan for Advanced Non-small Cell Lung Cancer(NSCLC) Harboring EGFR Mutations Concomitant With Human Epidermal Growth Factor Receptor 2(HER2) AlterationsAumolertinibPhase 2Not yet recruitingYongsheng WangJul 13, 2026
EGFR Targeted Photoimmunotherapy With ASP-1929 for Locally Advanced Pancreatic CancerCetuximab sarotalocanPhase 1 / Phase 2Not yet recruitingBrown UniversityJul 13, 2026
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal CancerPanitumumabPhase 2RecruitingVerastem, Inc.Jun 22, 2026
A Prospective Study of Firmonertinib as First-line Adaptive Therapy Guided by Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGFR-mutated Non-small Cell Lung CancerFirmonertinibPhase 2Not yet recruitingAnhui Provincial Cancer HospitalJun 22, 2026
OBSERVE: A Pilot Study Of Omission Of Brain Metastasis Stereotactic Radiosurgery Following Resection With CNS-Active Systemic TherapyBrigatinibPhase 1RecruitingM.D. Anderson Cancer CenterJun 18, 2026
Precision Medicine for Immunotherapy-Resistant Advanced Esophageal CancerAfatinib, PyrotinibPhase 2 / Phase 3Not yet recruitingPeking University Cancer Hospital & InstituteJun 17, 2026
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic CancerPanitumumabPhase 2RecruitingVerastem, Inc.Jun 12, 2026
PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLCAumolertinibPhase 1RecruitingHansoh BioMedical R&D CompanyJun 12, 2026
EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLCAumolertinibPhase 2RecruitingNanfang Hospital, Southern Medical UniversityJun 9, 2026
Aumolertinib Combined With Phased Chemotherapy for EGFR L858R Lung AdenocarcinomaAumolertinibPhase 2RecruitingTaipei Medical University HospitalJun 3, 2026
Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung AdenocarcinomaFirmonertinibPhase 2RecruitingPeking University Cancer Hospital & InstituteJun 3, 2026
Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell CarcinomaNimotuzumabPhase 2RecruitingShanghai General Hospital, Shanghai Jiao Tong University School of MedicineMay 22, 2026
A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLCAmivantamab, LazertinibPhase 2RecruitingJanssen Research & Development, LLCMay 14, 2026
Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung CancerAmivantamab—RecruitingGFPC InvestigationMay 1, 2026
Ablative Therapy of Oligometastatic Tumor After Response to Conventional First Line TreatmentPanitumumab—Not yet recruitingChirecApr 22, 2026
Postoperative Radiotherapy With Nimotuzumab ± Benmelstobart in Intermediate-Risk Head and Neck Squamous Cell CarcinomaNimotuzumabPhase 2 / Phase 3Not yet recruitingShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityApr 17, 2026
Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients With EGFR-mutant, Locally Advanced or Metastatic/Recurrent Non-Small Cell Lung Cancer (INSTAR Study)Amivantamab, LazertinibPhase 2Not yet recruitingYonsei UniversityApr 2, 2026
A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With OsteosarcomaGefitinibPhase 2RecruitingMemorial Sloan Kettering Cancer CenterMar 17, 2026
A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based RegimensAmivantamab, LazertinibPhase 4Not yet recruitingShanghai Pulmonary Hospital, Shanghai, ChinaMar 13, 2026
Therapy for Advanced NSCLC With EGFR 19delins MutationGefitinib, IcotinibEarly phase 1Not yet recruitingFuzhou General HospitalMar 9, 2026
Phase II Trial of Amivantamab Plus Monochemotherapy in Platinum Unfit NSCLC Patients With EGFR exon20 Insertion Mutations.AmivantamabPhase 2RecruitingFondazione Ricerca TraslazionaleFeb 6, 2026
Zorifertinib With Osimertinib for NSCLC With Meningeal ProgressionAZD-3759Phase 1RecruitingAlpha Biopharma (Jiangsu) Co., Ltd.Jan 23, 2026
A Prospective Multicenter Study of the Association Between TCM Syndromes and EGFR-TKI Efficacy in Lung Cancer PatientsErlotinib, Gefitinib—Not yet recruitingGuangzhou University of Traditional Chinese MedicineJan 13, 2026
Neratinib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breast CancerNeratinibPhase 2Not yet recruitingXijing HospitalJan 12, 2026
Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary AdenocarcinomaFirmonertinibPhase 2RecruitingHunan Cancer HospitalJan 2, 2026
Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mgFirmonertinibPhase 2Not yet recruitingPeking University Cancer Hospital & InstituteDec 23, 2025
A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World SettingLazertinib—RecruitingJanssen Research & Development, LLCNov 17, 2025
Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung CancerCLN-081Phase 2Not yet recruitingJonsson Comprehensive Cancer CenterNov 17, 2025
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon MutationsAfatinib, FirmonertinibPhase 3RecruitingArriVent BioPharma, Inc.Sep 22, 2025
High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLCFirmonertinibPhase 2Not yet recruitingPeking University Cancer Hospital & InstituteSep 19, 2025
An External Control Arm Study in Non-Small Cell Lung CancerLazertinib—RecruitingN-Power MedicineSep 15, 2025
RT for Adenocarcinoma/Adenosquamous CarcinomaNeratinibPhase 1 / Phase 2Active, not recruitingPeking Union Medical College HospitalSep 4, 2025
T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain MetastasisNeratinib, LapatinibPhase 2RecruitingFudan UniversitySep 3, 2025
A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) MetastasesErlotinib, Gefitinib—RecruitingAlpha Biopharma (Jiangsu) Co., Ltd.Aug 27, 2025
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor ResectionCLN-081Phase 3RecruitingTaiho Oncology, Inc.Aug 17, 2025
Neratinib in Extended Adjuvant Treatment for HER2+ Early Breast Cancer With pCR But High-Risk Features: A Hebei Multi-Center Real-World StudyNeratinib—Not yet recruitingHebei Medical University Fourth HospitalJun 13, 2025
A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell CarcinomaAfatinibPhase 1 / Phase 2Active, not recruitingWest China HospitalJun 8, 2025
Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States PopulationErlotinibPhase 2RecruitingMayo ClinicMay 30, 2025
Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver MutationsIcotinibPhase 3Not yet recruitingThe First Affiliated Hospital of Guangzhou Medical UniversityMay 2, 2025
Probiotics for Prevention of Neratinib-Induced Diarrhea in Breast Cancer PatientsNeratinibNot applicableRecruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityMar 24, 2025
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaMatuzumabPhase 2RecruitingShanghai Henlius BiotechMar 4, 2025
Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted TherapyNeratinib, LapatinibEarly phase 1RecruitingVanderbilt-Ingram Cancer CenterFeb 14, 2025
Using Tumor Models to Determine TreatmentsBrigatinib, NeratinibPhase 2RecruitingUniversity Health Network, TorontoFeb 6, 2025
FHND9041 Versus Afatinib for Non-small Cell Lung CancerAfatinibPhase 3Enrolling by invitationJiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.Jan 6, 2025
A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell CarcinomaAfatinibPhase 1 / Phase 2RecruitingWest China HospitalDec 31, 2024
A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive MutationsMatuzumabPhase 3RecruitingShanghai JMT-Bio Inc.Dec 16, 2024
Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLCAfatinibPhase 2RecruitingShandong Public Health Clinical CenterNov 29, 2024
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant MetastasesCetuximab sarotalocanPhase 3RecruitingRakuten Medical, Inc.Nov 21, 2024
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)LazertinibPhase 2RecruitingJanssen Research & Development, LLCOct 31, 2024
Afatinib in Patients With Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)AfatinibPhase 1 / Phase 2RecruitingFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauOct 18, 2024
Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by BrigatinibBrigatinibPhase 2RecruitingGroupe Francais De Pneumo-CancerologieOct 1, 2024
Epidermal Growth Factor Receptor Inhibition for KeratinopathiesErlotinibPhase 1 / Phase 2Not yet recruitingNorthwestern UniversityAug 9, 2024
Befotertinib and Icotinib for NSCLC With Uncommon EGFR MutationsIcotinibPhase 2RecruitingSun Yat-sen UniversityJul 24, 2024
Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxelErlotinibPhase 1 / Phase 2RecruitingUNC Lineberger Comprehensive Cancer CenterJul 3, 2024
EGFR-mutated Lung Cancer in Randomized Investigator-Initiated StudyAfatinibPhase 3RecruitingRegion SkaneJul 3, 2024
A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast CancerLapatinibPhase 3RecruitingTianjin Hemay Pharmaceutical Co., LtdMar 15, 2024
Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer PatientsGefitinibPhase 1 / Phase 2RecruitingChina Medical University HospitalOct 6, 2023
Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive MutationsIcotinibPhase 3RecruitingBetta Pharmaceuticals Co., Ltd.Sep 18, 2023
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)CLN-081Phase 3Active, not recruitingTaiho Oncology, Inc.Aug 3, 2023
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.CLN-081Phase 2RecruitingTaiho Oncology, Inc.Aug 1, 2023
A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC) ENTIRETYBrigatinib—Active, not recruitingTakedaFeb 21, 2023
A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC)Brigatinib—Active, not recruitingTakedaFeb 10, 2023
Adjuvant Treatment Based on MRD for EGFR Mutant NSCLCIcotinibPhase 2RecruitingGuangdong Association of Clinical TrialsSep 13, 2022
Antineoplastic Drugs in Elderly PatientsLapatinib—RecruitingShandong UniversityJul 20, 2022
Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR MutationsGefitinibPhase 3RecruitingInstituto Nacional de Cancerologia de MexicoJul 6, 2022
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)BrigatinibPhase 1 / Phase 2RecruitingNuvalent Inc.May 20, 2022
Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)BrigatinibPhase 2Active, not recruitingIntergroupe Francophone de Cancerologie ThoraciqueJan 20, 2022
Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung CancerNecitumumabPhase 1 / Phase 2Active, not recruitingJonsson Comprehensive Cancer CenterFeb 26, 2020
Implantable Microdevice In Primary Brain TumorsLapatinibEarly phase 1RecruitingOliver JonasOct 23, 2019
A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung CancerCLN-081Phase 1 / Phase 2Active, not recruitingCullinan Therapeutics Inc.Jul 30, 2019
Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)NecitumumabPhase 2Active, not recruitingAstraZenecaMay 10, 2019
A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung CancerMobocertinibPhase 1Active, not recruitingTakedaJan 17, 2019
Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLCNazartinibPhase 1Active, not recruitingNovartis PharmaceuticalsNov 6, 2017
Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment AloneNazartinibPhase 2Active, not recruitingNovartis PharmaceuticalsFeb 2, 2017
Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase InhibitorNecitumumabPhase 1Active, not recruitingNational Cancer Institute (NCI)Jul 14, 2015
SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast CancerSapitinibPhase 2Active, not recruitingUNICANCERNov 24, 2014
Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatmentLapatinibPhase 2RecruitingCentre Leon BerardJan 7, 2014
Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by SurgeryLapatinibPhase 1Active, not recruitingNational Cancer Institute (NCI)Sep 20, 2013
Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast CancerLapatinibPhase 2Active, not recruitingCity of Hope Medical CenterJan 10, 2011

Diseases most associated with it

Open Targets association score, 0 to 1; all associations
Non-small cell lung carcinoma
0.85
Lung adenocarcinoma
0.77
Cancer
0.74
Head and neck squamous cell carcinoma
0.72
Colorectal adenocarcinoma
0.68
Neoplasm
0.65
Inflammatory skin and bowel disease, neonatal, 2
0.64

Genes and related targets

Complexes and families that share a gene with this target
Genes
EGFR

Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL203, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P00533, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.